Patents Represented by Attorney Francis J. Tinney
  • Patent number: 8258315
    Abstract: A process for forming amorphous atorvastatin comprising the steps of dissolving atorvastatin in a non-hydroxylic solvent and removing the solvent by freeze-drying, as well as processes of dissolving atorvastatin in a hydroxylic solvent with a solubilizing agent or an alkalizing agent or an antioxidant and removing the solvent by freeze-drying to afford amorphous atorvastatin.
    Type: Grant
    Filed: April 4, 2011
    Date of Patent: September 4, 2012
    Assignee: Pfizer Inc.
    Inventors: Antone J deBettencourt, III, Peter R. Rose, Evgenyi Shalaev, George J. Quallich, Carl B. Ziegler, Jr.
  • Patent number: 8236966
    Abstract: Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease.
    Type: Grant
    Filed: December 13, 2010
    Date of Patent: August 7, 2012
    Assignee: Pfizer Inc.
    Inventors: Joseph F. Krzyzaniak, Jason Albert Leonard
  • Patent number: 8084488
    Abstract: Novel forms of atorvastatin magnesium salt designated Form A, Form B, Form C, Form D, Form E, and Form F, pharmaceutical compositions containing such compounds, methods for their preparation and methods utilizing the compounds for treatment of hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia (BPH) and Alzheimer's disease are described.
    Type: Grant
    Filed: November 9, 2006
    Date of Patent: December 27, 2011
    Assignee: Pfizer Inc.
    Inventors: Jason A. Leonard, Jonathan M. Miller
  • Patent number: 8026376
    Abstract: Novel forms of [R-(R*,R*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4 -[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt designated Form XX, Form XXI, Form XXII, Form XXIII, Form XXIV, Form XXV, Form XXVI, Form XXVII, Form XXVIII, Form XXIX, and Form XXX, characterized by their X-ray powder diffraction, solid-state NMR, and/or Raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia (BPH) and Alzheimer's disease.
    Type: Grant
    Filed: July 11, 2005
    Date of Patent: September 27, 2011
    Assignee: Pfizer, Inc.
    Inventors: Joseph F. Krzyzaniak, George M. Laurence, Aeri Park, Kevin J. Quackenbush, Marie L. Reynolds, Peter R. Rose, Timothy A. Woods
  • Patent number: 7875731
    Abstract: Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease.
    Type: Grant
    Filed: April 25, 2005
    Date of Patent: January 25, 2011
    Assignee: Pfizer Inc.
    Inventors: Anthony Michael Campeta, Joseph F. Krzyzaniak, Jason Albert Leonard
  • Patent number: 7183408
    Abstract: An improved process for the preparation of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide by a novel synthesis is described where methyl cyanoacetate is converted in eight operations or fewer to the desired product, as well as other valuable intermediates used in the process.
    Type: Grant
    Filed: April 19, 2005
    Date of Patent: February 27, 2007
    Assignee: Warner-Lambert Company, LLC
    Inventors: Donald Eugene Butler, Randall Lee DeJong, Jade Douglas Nelson, Michael Gerard Pamment, Timothy Lee Stuk
  • Patent number: 7144915
    Abstract: Novel crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt designated Form V, Form VI, Form VII, Form VIII, Form IX, Form X, Form XI, Form XII, Form XIII, Form XIV, Form XV, Form XVI, Form XVII, Form XVIII, and Form XIX are characterized by their X-ray powder diffraction, solid-state NMR, and/or Raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, and Alzheimer's disease.
    Type: Grant
    Filed: June 6, 2003
    Date of Patent: December 5, 2006
    Assignee: Warner-Lambert Company, LLC
    Inventors: Stephen Robert Byrn, David Andrew Coates, Karen Sue Gushurst, Joseph Francis Krzyzaniak, Zheng Jane Li, Henry Grant Morrison, II, Aeri Park, Petinka Ivanova Vlahova
  • Patent number: 6962994
    Abstract: An improved process for the preparation of cis-1,3-diols is described where a beta hydroxy ketone is treated with a trialkylborane or dialkylalkoxyborane or a mixture of a trialkylborane and a dialkylalkoxyborane followed by recovery and reuse of the alkylborane species to convert additional beta hydroxy ketone to the cis-1,3-diol.
    Type: Grant
    Filed: April 11, 2003
    Date of Patent: November 8, 2005
    Assignee: Warner-Lambert Company, LLC
    Inventors: Robert Lee Bosch, Richard Joseph McCabe, Thomas Norman Nanninga, Robert Joseph Stahl
  • Patent number: 6933393
    Abstract: An improved process for the preparation of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide by a novel synthesis is described where methyl cyanoacetate is converted in eight operations or fewer to the desired product, as well as other valuable intermediates used in the process.
    Type: Grant
    Filed: January 21, 2003
    Date of Patent: August 23, 2005
    Assignee: Warner-Lambert Company LLC
    Inventor: Donald Eugene Butler
  • Patent number: 6886698
    Abstract: Spent pyrophoric reaction catalyst from a reaction mixture is removed safely, cheaply, and rapidly using a single plate pressure filter. After hydrogenation, the reaction mixture is decanted, the desired hydrogenation product is removed, and catalyst-rich material which settles at the bottom of the vessel is delivered to a single plate pressure filter fitted with a filter bag 40 of permeable material. The spent catalyst is retained in the filter bag 40 and stored under water awaiting recovery. The filter apparatus 1 comprises a container having a domed base 2, a generally cylindrical sidewall 3 terminating in an upper rim 4 closed by a lid 5 having lifting lugs 6. The lid 5 is fixed in pressure-tight engagement with the sidewall 3 by flange engaging screw clamps 7 and an embedded polytetrafluoroethene gasket 8. The filter bag 40 is held in position by a band 11 and may be readily released for removal of the spent catalyst material. The bag 40 may be reused.
    Type: Grant
    Filed: June 14, 2002
    Date of Patent: May 3, 2005
    Assignee: Warner-Lambert Company
    Inventor: William Tully
  • Patent number: 6814878
    Abstract: A batch process for carrying out a hydrogenation reaction comprises mixing a pyrophoric catalyst with reactants and solvents to form a reaction mixture in a reaction vessel. Hydrogen is added to the reaction vessel. After hydrogenation, the desired hydrogenation product is removed from the reaction vessel and the pyrophoric catalyst-rich material from the reaction vessel is delivered to a pressure filter. Water is added to the pyrophoric catalyst-rich material in the filter and the spent pyrophoric material is removed from the pressure filter in a water wet form.
    Type: Grant
    Filed: June 2, 2003
    Date of Patent: November 9, 2004
    Assignee: Pfizer Science and Technology Ireland Limited
    Inventor: William Tully
  • Patent number: 6730797
    Abstract: A factory scale process for producing crystalline atorvastatin calcium includes the step of drying the isolated product in a vacuum pan dryer. The vacuum pan dryer has an agitator which is continuously rotated at a speed of approximately 1 rpm. High quality material is routinely and consistently produced with reduced cycle time.
    Type: Grant
    Filed: August 8, 2003
    Date of Patent: May 4, 2004
    Assignee: Pfizer Science and Technology Ireland Limited
    Inventors: John O'Connell, William Tully, Evelyn Madigan
  • Patent number: 6689915
    Abstract: Non-C2-symmetric bisphospholane ligands and methods for their preparation are described. Use of metal/non-C2-symmetric bisphospholane complexes to catalyze asymmetric transformation reactions to provide high enantiomeric excesses of formed compounds is also described.
    Type: Grant
    Filed: February 27, 2002
    Date of Patent: February 10, 2004
    Assignee: Warner-Lambert Company LLC
    Inventors: Garrett Stewart Hoge, II, Om Prakash Goel
  • Patent number: 6684526
    Abstract: An improved process for removing trace solvent from a material comprises rewetting the product with water during the drying process. Finished products such as suramin are produced efficiently to a high quality on a factory scale.
    Type: Grant
    Filed: June 14, 2002
    Date of Patent: February 3, 2004
    Assignee: Pfizer Science and Technology Ireland, Limited
    Inventor: William Tully
  • Patent number: 6620314
    Abstract: A unit 1 for producing pyrogen controlled water on a small to medium factory scale comprises a number of charged ultrafiltration units 10 arranged in parallel. Orifice plates 15 are used to restrict and control the flow of deionized water to each filter 10. The filter units 10 are mounted on a frame 2 with a wheeled chassis 3 which may be pushed or moved by a forklift truck to a site where pyrogen controlled water is required. The unit 1 has an inlet line 4 for connection to a supply of deionized water and an outlet line 6 for connection to a user of pyrogen controlled water. The unit 1 may be purged with nitrogen from a supply 18. Sampling ports 17 in a common supply inlet 4 and a common outlet 6 ensure that the filtration efficiency can be closely monitored. The flow of water is monitored by a flowmeter 19 and pressure sensors 16 upstream of each filter facilitate a high level of control.
    Type: Grant
    Filed: June 14, 2002
    Date of Patent: September 16, 2003
    Assignee: Warner-Lambert Company
    Inventors: William Tully, Evelyn Madigan
  • Patent number: 6605729
    Abstract: Novel crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-&bgr;,&dgr;-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt designated Form V, Form VI, Form VII, Form VIII, Form IX, Form X, Form XI, Form XII, Form XIII, Form XIV, Form XV, Form XVI, Form XVII, Form XVIII, and Form XIX are characterized by their X-ray powder diffraction, solid-state NMR, and/or Raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, and Alzheimer's disease.
    Type: Grant
    Filed: June 28, 2002
    Date of Patent: August 12, 2003
    Assignee: Warner-Lambert Company
    Inventors: Stephen Robert Byrn, David Andrew Coates, Karen Sue Gushurst, Joseph Francis Krzyzaniak, Zheng Jane Li, Henry Grant Morrison, II, Aeri Park, Petinka Ivanova Vlahova
  • Patent number: 6605728
    Abstract: A factory scale process for producing crystalline atorvastatin calcium includes the step of drying the isolated product in a vacuum pan dryer. The vacuum pan dryer has an agitator which is continuously rotated at a speed of approximately 1 rpm. High quality material is routinely and consistently produced with reduced cycle time.
    Type: Grant
    Filed: June 14, 2002
    Date of Patent: August 12, 2003
    Assignee: Warner-Lambert Company
    Inventors: John O'Connell, William Tully, Evelyn Madigan
  • Patent number: 6600051
    Abstract: A factory scale process for producing crystalline atorvastatine trihydrate hemi calcium salt includes the addition of extra methyl tert-butyl ether to the reaction mixture to supersaturate the crystallization matrix. A seed slurry is made up in a make-up/delivery vessel and delivered, under pressure, to the reaction mixture. The process produces crystalline atorvastatin calcium within a consistent size range on a factory scale.
    Type: Grant
    Filed: June 14, 2002
    Date of Patent: July 29, 2003
    Assignee: Warner-Lambert Company
    Inventor: William Tully
  • Patent number: 6596879
    Abstract: An improved process for the preparation of cis-1,3-diols is described where a beta hydroxy ketone is treated with a trialkylborane or dialkylalkoxyborane or a mixture of a trialkylborane and a dialkylalkoxyborane followed by recovery and reuse of the alkylborane species to convert additional beta hydroxy ketone to the cis-1,3-diol.
    Type: Grant
    Filed: June 11, 2002
    Date of Patent: July 22, 2003
    Assignee: Warner-Lambert Company
    Inventors: Robert Lee Bosch, Richard Joseph McCabe, Thomas Norman Nanninga, Robert Joseph Stahl
  • Patent number: 6545153
    Abstract: An improved process for the preparation of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide by a novel synthesis is described where methyl cyanoacetate is converted in eight operations or fewer to the desired product, as well as other valuable intermediates used in the process.
    Type: Grant
    Filed: July 18, 2002
    Date of Patent: April 8, 2003
    Assignee: Warner-Lambert Company
    Inventors: Donald Eugene Butler, Randall Lee Dejong, Jade Douglas Nelson, Michael Gerard Pamment, Timothy Lee Stuk